Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pineapple, Inc. (PNPL)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Pharmaceuticals
Address
10351 Santa Monica Boulevard 90025
Los Angeles, CA, US
Los Angeles, CA, US
CEO
Shawn Credle
Website
pineappleinc.com
IPO
1998-12-14
CIK 1654672 ISIN US72303J1016
Description
Serving the cannabis industry, Pineapple, Inc. functions as a portfolio management firm. Its extensive asset portfolio encompasses a range of offerings, including operational guidance, technological support, intellectual property rights, and real estate rentals tailored for cannabis enterprises. The company also maintains equity investments in both retail and manufacturing segments of the cannabis market. Beyond these, Pineapple extends financing to its cannabis-focused clients, manages property leases for them, and delivers consulting services and technological expertise to facilitate the growth, enhancement, or establishment of new and existing business structures. Established in 1983, the firm's main offices are located in Los Angeles, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.0K
Beta
3.44
Float Shares
29.71M
Free Float %
40.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -38.10% | -66.19% | -76.36% | -80.00% | -74.00% | +30.00% | -99.89% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-4.62
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+10.0% ★ Q3'25: -98.8% (vs Q3'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%+5.9% Q3'25: +100.0% (vs Q3'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-28.1% Q3'25: -12,702.7% (vs Q3'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-334.8% Q3'25: -135.5% (vs Q3'24)
-
ROIC Medical - Pharmaceuticals: +6.1%-28.6% Q3'25: -0.2% (vs Q3'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.9% Q3'25: 0.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-5.70× Q3'25: -1,141.82× (vs Q3'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
1.14M
OE per share TTM
0.02
Owner's Yield
59.72%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1,794.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
4
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jaime Ortega | 45.79M | 52.70% | — | 45.79M | — | 10.00 | IN | OR PLACE OF ORGANIZATION | 2019-11-26 | ↗ |
| 2 | Matthew Feinstein | 27.89M | 39.20% | — | — | 27.89M | 10.00 | IN | OR PLACE OF ORGANIZATION | 2023-03-30 | ↗ |
| 3 | Anna Mikhaylova | 7.27M | 10.00% | — | — | 7.27M | — | IN | United States America | 2023-05-15 | ↗ |
| 4 | Joshua Eisenberg | 5.00M | 6.50% | — | — | 5.00M | 10.00 | IN | OR PLACE OF ORGANIZATION | 2019-11-20 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.25
Bearish
Ratio by volume
0.51
Neutral
Buys
1
Sells
4
Shares acquired
20.79M
Shares disposed
40.79M
Cash buys
3.00
Cash sales
—
Net activity
-20,000,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-10 | Ortega Jaime | 10% Owner | S-Sale | D | Common Shares | 20,790,000 | 0.00 | 41.6K | 3,124,000 | — | ↗ |
| 2023-01-10 | Feinstein Matthew | Director / Officer / 10% Owner | P-Purchase | A | Common Shares | 20,790,000 | 0.00 | 41.6K | 27,890,000 | — | ↗ |
| 2022-12-31 | Ortega Jaime | 10% Owner | S-Sale | D | Common Shares | 20,000,000 | 0.00 | — | 23,914,000 | — | ↗ |
| 2021-12-19 | Rullo Gianmarco | Officer | A-Award | A | Common Stock, $0.0000001 par value | 500,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2021-12-19 | Hurwitz Randy J | Director | A-Award | A | Common Stock, $0.0000001 par value | 132,000 | 0.00 | — | 639,000 | — | ↗ |
| 2021-12-19 | Eisenberg Joshua | Officer | A-Award | A | Common Stock, $0.0000001 par value | 200,000 | 0.00 | — | 5,200,000 | — | ↗ |
| 2021-12-19 | Credle Shawn | Officer | A-Award | A | Common Stock, $0.0000001 par value | 500,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2021-06-24 | Rullo Gianmarco | Officer | A-Award | A | Common Stock, $0.0000001 par value | 260,000 | 0.00 | — | 500,000 | — | ↗ |
| 2021-06-24 | Hurwitz Randy J | Director | A-Award | A | Common Stock, $0.0000001 par value | 50,000 | 0.00 | — | 595,000 | — | ↗ |
| 2021-06-24 | Hill Katherine | Director | A-Award | A | Common Stock, $0.0000001 par value | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2021-05-31 | Hill Katherine | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-05-29 | Rullo Gianmarco | Officer | — | D | Common Stock, $0.0000001 par value | 0 | 0.00 | — | 240,000 | — | ↗ |
| 2020-04-14 | Hurwitz Randy J | Director | A-Award | A | Common Stock, $0.0000001 par value | 100,000 | 0.00 | — | 545,000 | — | ↗ |
| 2019-06-18 | Hurwitz Randy J | Director | — | D | Common Stock, Par Value $0.0000001 | 0 | 0.00 | — | 445,000 | — | ↗ |
| 2019-05-30 | Credle Shawn | Officer | A-Award | A | Common Stock, $0.0000001 par value | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2019-04-02 | Ortega Jaime | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 43,914,000 | — | ↗ |
| 2019-04-02 | Eisenberg Joshua | Officer | A-Award | A | Common Stock, $0.0000001 par value | 5,000,000 | 0.00 | — | 5,000,000 | — | ↗ |
| 2019-02-05 | Eisenberg Joshua | Officer | — | D | Common Stock, $0.0000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-02-05 | Credle Shawn | Officer | — | D | Common Stock, $0.0000001 par value | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-03-26 | Kennedy Eric M | Director / 10% Owner | — | D | Common Stock, $0.0000001 par value | 0 | 0.00 | — | 30,935,000 | — | ↗ |
| 2018-03-26 | Feinstein Matt | Director / Officer / 10% Owner | — | D | Common Stock, $0.0000001 par value | 0 | 0.00 | — | 7,100,000 | — | ↗ |
| 2015-08-24 | Mikhaylova Anna | 10% Owner | — | D | Common Stock, $0.0000001 par value | 0 | 0.00 | — | 7,273,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
73.10M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matthew Feinstein | Co-Founder, Chairman, Secretary & Chief Financial Officer | 108.0K | male |
| Shawn Credle | Chief Executive Officer & Director | 48.0K | male |
| Gianmarco Rullo | President | — | male |
| Vincent Mehdizadeh | Founder & Senior Advisor of Technology | — | male |
ESG Rating
ESG Score History MEDICAL - PHARMACEUTICALS
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PNPL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
